Bringing the Oncology Community Together

Dr. Aft on Bisphosphonates for Breast Cancer

Rebecca L. Aft, MD, PhD
Published Online: Wednesday, September 18, 2013
Rebecca L. Aft, MD, PhD, professor of surgery at the Washington University School of Medicine in St. Louis and a physician at Siteman Cancer Center, discusses the use of bisphosphonates for patients with breast cancer.

In a study, patients were randomized to receive a bisphosphonate at the time of neoadjuvant chemotherapy and were analyzed for the presence of disseminating tumor cells. Results demonstrated that patients who received a bisphosphonate had fewer disseminating tumor cells in their bone marrow. In a subgroup analysis, patients with triple-negative disease who received bisphosphonates had a decreased risk of developing metastatic disease.

The mechanism of action of bisphosphonates is hypothesized to affect the bone marrow's microenvironment. It is also hypothesized that cancer cells in the bone marrow or tumors can release activators into the bone marrow which cause increased bone turnover and activation of tumor-enhancing cells. By turning off osteoclasts, Aft says, it is possible to decrease bone turnover and decrease the release of growth factors, creating a more hostile environment for disseminating tumor cells in the bone marrow.

Related Articles
Phase III Clinical Trials in HER2-Positive Breast Cancer
Expert panelists explore several large clinical trials examining therapies for patients with HER2-positive breast cancer that are currently ongoing or have recently completed.
Experts Support Broader Pertuzumab Use in HER2-Positive Breast Cancer
The recent approval of pertuzumab as part of a combination neoadjuvant treatment for patients with early-stage breast cancer has paved the way for wider use of the regimen in preoperative settings.
New ASCO Guideline Expands Recommendation for SLN Biopsy Use in Early Stage Breast Cancer
An updated guideline from ASCO regarding the use of sentinel lymph node (SLN) biopsy in early stage breast cancer supports the use of the procedure over axillary lymph node dissection (ALND) in a larger group of patients than previously recommended.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.